An antifungal antibiotic (S) 2-amino-4-oxo-5-hydroxypentanoic acid, inhibited the biosynthesis of the aspartate family of amino acids (methionine, isoleucine and threonine) followed by the inhibition of protein biosynthesis in Saccharomyces cerevisiae. This inhibition was effected by impeding the biosynthesis of their commonintermediate precursor, homoserine. The recent increase of opportunistic fungal infection prompted us to search for new types of antifungal agents. In our program for screening of antifungal agents, we isolated an amino acid analog, (S) 2-amino-4-oxo-5-hydroxypentanoic acid ( Fig. 1 ) coded as RI-331, from a culture broth of Streptomyces sp. The antibiotic had in vitro activity against several pathogenic fungi of medical importance, including Candida albicans and Cryptoccocus neoformans, and was effective in the treatment of systemic murine candidiasis being highly tolerated in mice1*. Our major concern was to understand the molecular basis of the selective antifungal action of the antibiotic. Our initial studies with growing cells of Saccharomyces cerevisiae showed that RI-331 preferentially lowered the cellular level of three aspartate family amino acid (viz threonine, methionine and isoleucine). Also the antifungal action of RI-331 was antagonized by these amino acids and, to a greater extent, by their metabolic precursor homoserine, suggesting that the site of action of the antibiotic maybe on the metabolic step(s) involved in the biosynthesis of homoserine or its precursor2'3). This hypothesis was confirmed by the results of studies with the enzymatic system prepared from yeast cells; homoserine dehydrogenase involved in the conversion of aspartate semialdehyde to homoserine was significantly inhibited by the antibiotic4) In this publication the kinetics of this inhibition of homoserine dehydrogenase by the antibiotic are described. f Present
The recent increase of opportunistic fungal infection prompted us to search for new types of antifungal agents. In our program for screening of antifungal agents, we isolated an amino acid analog, (S) 2-amino-4-oxo-5-hydroxypentanoic acid ( Fig. 1 ) coded as RI-331, from a culture broth of Streptomyces sp. The antibiotic had in vitro activity against several pathogenic fungi of medical importance, including Candida albicans and Cryptoccocus neoformans, and was effective in the treatment of systemic murine candidiasis being highly tolerated in mice1*. Our major concern was to understand the molecular basis of the selective antifungal action of the antibiotic. Our initial studies with growing cells of Saccharomyces cerevisiae showed that RI-331 preferentially lowered the cellular level of three aspartate family amino acid (viz threonine, methionine and isoleucine). Also the antifungal action of RI-331 was antagonized by these amino acids and, to a greater extent, by their metabolic precursor homoserine, suggesting that the site of action of the antibiotic maybe on the metabolic step(s) involved in the biosynthesis of homoserine or its precursor2'3). This hypothesis was confirmed by the results of studies with the enzymatic system prepared from yeast cells; homoserine dehydrogenase involved in the conversion of aspartate semialdehyde to homoserine was significantly inhibited by the antibiotic4) In this publication the kinetics of this inhibition of homoserine dehydrogenase by the antibiotic are described. Preparation of Enzymes Aspartate kinase was purified from either S2614C or STX25-2Amutant strain by the method as described by Black et al.5) . Aspartate semialdehyde dehydrogenase was purified from the hom6 mutant, STX25-2A(lacking homoserine dehydrogenase), and homoserine dehydrogenase was purified from the homl mutant, S2614C (lacking aspartate semialdehyde dehydrogenase) as described elsewhere6>7). The enzymes were further purified by column chromatography of DEAE cellulose (DE52) and then hydroxyapatite.
EnzymeReactions
Aspartate kinase activity was determined by measuring the rate of forward reaction. The reaction mixture contained 100mMTris-HCl, pH 8.0, 100him L-aspartic acid, 20mMATP, 20mMMgCl2, 400mM hydroxylamine hydrochloride and 200fig of aspartate kinase in a final volume of 1 ml. Incubation was at 27°C for 30 minutes, in which aspartylhydroxamate is formed by the interaction of aspartylphosphate with hydroxylamine. Then, 1 ml of 5% FeCl3 -6H2O dissolved in 0.1 n HC1 was added and the absorbance of aspartylhydroxamate-iron complex formed was measured at 540 nm5).
Aspartate semialdehyde dehydrogenase activity coupled with aspartate kinase and aspartate semialdehyde dehydrogenase was measured in the forward reaction by following NADPHdisappearance monitored by the decrease of absorbance at 340nm. The reaction mixture contained 100mMTris-HCl, pH 8.0, 100mML-aspartic acid, 20mMATP, 20mMMgCl2, 0.08mM NADPH,aspartate kinase 100pg and aspartate semialdehyde dehydrogenase 20/ig in a total volume of 1 ml. Incubation was at 27°C.
Homoserine dehydrogenase activity in the forward reaction was measured by NADPH disappearance monitored by reduction of absorbance at 340nm. The reaction mixture contained 100mM potassium phosphate buffer pH 6.7, 0.08mMNADPH,10jug of homoserine dehydrogenase and 0.1 mMaspartate semialdehyde was incubated at 27°C. Homoserine dehydrogenase activity in the reverse reaction was measured by NADPHproduction corresponding to the increase of absorbance at 340 nm. The reaction mixture contained 100 mMTris-HCl, pH 9.0, 0.2 mMNADP, 10^g homoserine dehydrogenase, and 100 mMhomoserine. Incubation was at 27°C.
Chemicals: L-Aspartic acid, L-aspartylhydroxamate, L-homoserine, hydroxylamine-HCl, ATP, NADP and NADPHwere purchased from Sigma Chemical Co. Ltd., St. Louis, MO. RI-331 and aspartate semialdehyde were kindly supplied by Taisho Pharmaceutical Co. Ltd, Ohmiya City, Saitama prefecture, Japan.
Results

Effect of RI-331 on Aspartate Kinase and Aspartate
Semialdehyde Dehydrogenase The aspartate kinase activity of strains S2614C or STX25-2Awas not inhibited by RI-331 at 5mM (Table 1) , nor was the aspartate semialdehyde dehydrogenase involved in converting aspartylphosphate to aspartate semialdehyde, significantly affected by the antibiotic at such high concentration ( Table 2) .
Effect of RI-331 on Homoserine Dehydrogenase Homoserine dehydrogenase activity in the forward reaction, determined by NADPHdehydrogenation depending on added substrate aspartate semialdehyde (ASA), was significantly inhibited by the antibiotic. The inhibition of the enzyme activity was enhanced, if NADPwas added to the reaction mixture at high O +RI-331 5mM, A +RI-331 1mM, à" noaddition of RI-331
Control; no addition of RI-331, expressed by 100°/ Incubation was at 27°C for 10 minutes. 1/v; mmol *à"30minutesà"mg.
concentrations relative to NADPH (Fig. 2) . NADPwas added to the reaction mixture despite not being required in the forward reaction, but the addition of NADPwas essential for exhibition of inhibition of the forward reaction by the antibiotic. The rate of the forward reaction of control (without RI-331) was not affected by addition of NADP.These results presumably indicate that RI-331 may interact with the enzyme-NADPcomplex and then enzyme inhibition take place. The inhibition was the mixed type of competitive and noncompetitive inhibition with respect to ASAwith a Ki value of 2mMvs. a Kmvalue of 0.05him at a concentration of NADP0.2mM, and the reaction was inhibited at a high concentration of the substrate ASA itself more than 0.04mM (substrate inhibition) (Fig. 3) . The inhibition of this forward reaction by the antibiotic was noncompetitive with respect to NADP, and the association constant for NADP in the presence of the antibiotic revealed two values of 0.4 and 2mM,respectively, as analyzed by Dixon-plot (Fig. 4) , suggesting that the enzyme might interact with the antibiotic in two ways to give tertiary complexes (enzyme, NADPand antibiotic) of differing stabilities.
Homoserine dehydrogenase was more significantly inhibited by the antibiotic in the reverse reaction than in the forward reaction. The inhibition was competitive with respect to the substrate homoserine showing a Ki value of 0.025mMvs. Kmvalue of 17 mM (Fig. 5) . At a physiological concentration of NADP0.2mM, the enzyme was at least 10 times more susceptible to the antibiotic in the reverse reaction than in the forward reaction (Fig. 6) .
Moreover, prior exposure of the enzyme to NADP before starting the reaction enhanced the extent of inhibition of the enzyme in the reverse reaction (Fig.   7 ).
A; no addition of RI-331, B and C; NADPand homoserine were last added to the reaction mixture, Abbreviations: Enz; homoserine dehydrogenase from Saccharomyces cerevisiae, ASA;Aspartate semialdehyde, HS; homoserine, (F); forward reaction, (R); reverse reaction.
Discussion
Our preceding hypothesis, that the antifungal activity of RI-331 is due to the inhibition of the biosynthesis of the aspartate family of amino acids including threonine, methionine and isoleucine, followed by the inhibition of protein synthesis2'3), was confirmed with the demonstration of inhibition of homoserine biosynthesis by the antibiotic40. In the pathway from aspartate to homoserine, three enzymes (aspartate kinase, aspartate semialdehyde dehydrogenase and homoserine dehyrogenase) are involved. The former two enzymes, aspartate kinase and aspartate semialdehyde dehydrogenase were refractory to the antibiotic (Tables 1 and 2 ). The last enzyme, homoserine dehydrogenase, was however, found to be a target of RI-331. The kinetics of inhibition by the antibiotic of homoserine dehydrogenase highly purified from Saccharomyces cerevisiae were described here. Homoserine dehydrogenase activity in the forward reaction was inhibited by the addition of NADPinto the reaction mixture (Figs. 2 and 3) . The possibility that the enzyme-NADP complex may be formed first, followed by interaction with the antibiotic leading to inactivation of the enzyme (Fig. 8) , can be supported by the significant inhibition by the antibiotic of the enzymein the reverse reaction in which enzyme-NADP complex formation is a essential step to reaction (Figs. 5, 6 and 7). The experimental data could be explained if binding of NADPwere to induce a conformational change in the enzyme and if this were facilitate binding of the antibiotic, and thus the inactive enzyme-NADP-RI-33 1 complex could accumulate in the antibiotic-treated yeast cells as the enzyme activity decreases. A large number of amino acid analogs have been developed as antimetabolites so far, some of which exhibit antifungal activity. The majority of effective compoundshave been chemically synthesized, although somewere natural products, isolated either as antibiotics or substances toxic to animals8'9). Wewill describe here other amino acid compounds which are possibly available against fungal infections. A recent paper VOL.45 NO.5 THE JOURNAL OF ANTIBIOTICS 755 describes a promising amino acid antifungal antibiotic, cispentacinlo'1 1) identical to FR10961512) which is effective in treating candidiasis in mice and has low toxicity to these animals. Moreover, other types of inhibitors which prevent the biosynthesis of essential amino acids other than threonine, isoleucine and methione may also be useful for antifungal chemotherapy, as is RI-331.
Thus, the preferential inhibition by RI-33 1 of biosyntheses of threonine, methionine, and isoleucine, due to the inhibition of homoserine dehydrogenase (an enzyme not present in animal cells) can account for selective toxicity of the antibiotic against pathogenic fungi.
